Session Details
 N20104 - Overview of Immunotherapy Toxicity in Oncology: A Focus on CAR-T and Checkpoint Inhibitors
Tuesday, May 19, 2020
01:00 PM - 02:00 PM
$0     CME 
Location: 202
Immunotherapy is a type of cancer therapy that uses the patients immune system to fight the disease. This modulation of the immune system carries unique toxicities that should be understood by those who may encounter these patients. Two therapies with rapid growth and noteworthy toxicity are immune checkpoint inhibitors and Chimeric antigen receptor (CAR) T cell therapy. Checkpoint inhibitors are drugs that block immune checkpoints thus allowing a stronger response to the cancer. CAR-T cell therapy is of increasing importance in oncology. Hundreds of early phase clinical trials explore the future of CAR-T in solid and liquid tumors. Axicabtagene ciloleucel and Tisagenlecleucel are CD19-directed CAR-T therapies that are FDA approved to treat Diffuse Large B Cell Lymphoma in adults and Acute Lymphoblastic Leukemia in children. The two major CAR-T toxicities, cytokine release syndrome and neurologic toxicity, can be quite serious requiring specific pharmacologic therapies and multi disciplinary care.

At the end of this session, participants should be able to:

• Describe the cellular engineering and mechanism of action of CAR-T cells
• Describe chemotherapy conditioning and patient selection for CAR-T therapy
• Explain manifestations and management of adverse effects of CAR-T therapy including cytokine release syndrome, marrow suppression, and neurologic toxicity
• Describe what checkpoint inhibitors are used for and their mechanism of action
• Explain manifestations and management of immune mediated effects of checkpoint inhibitors including thyroid dysfunction, colitis, and other toxicities


No faculty found.